ASH 2024 – AbbVie fights to rise above the BCMA crowd
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
Incyte hopes to sneak Zynyz through the back door
In first-line NSCLC the drug beats chemo, and not Keytruda.
ASH 2024 – J&J reveals more about Lava's secret sauce
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
ASH 2024 – Miltenyi throws its hat into the fast-Car ring
And the company might one day follow Galapagos into decentralised manufacturing.
ASH 2024 – Galapagos turns Car-T manufacturing on its head
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
Biohaven aims to become an oncology fast follower
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
A fourth challenger from DualityBio and BioNTech
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
Protara could take on J&J
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
Gilead and GSK nab early ADCs
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
BioNTech's pivotal bispecifics plan take shape
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
